Ascelia Pharma AB (publ) (STO:ACE)

Market Cap	371.09M +25.4%
Revenue (ttm)	n/a
Net Income	-76.25M
EPS	-0.67
Shares Out	126.87M
PE Ratio	n/a
Forward PE	11.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,092,874
Average Volume	1,101,486
Open	2.955
Previous Close	2.925
Day's Range	2.925 - 3.120
52-Week Range	2.305 - 5.230
Beta	0.84
RSI	51.50
Earnings Date	Feb 5, 2026

About Ascelia Pharma AB

Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. Ascelia Pharma AB (publ) was incorporated in 1999 and is headq...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 11
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ACE